Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the highest response rates are found with Inlyta (axitinib) as a partner.
You may also be interested in...
In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.
A global collaboration potentially valued at nearly $6bn will see Eisai's oral tyrosine kinase inhibitor lenvatinib being evaluated in combination with Keytruda in multiple cancer types and indications.
Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.